LV11784B - Fibrin-specific antibody for use as an antithrombotic agent - Google Patents
Fibrin-specific antibody for use as an antithrombotic agent Download PDFInfo
- Publication number
- LV11784B LV11784B LVP-96-379A LV960379A LV11784B LV 11784 B LV11784 B LV 11784B LV 960379 A LV960379 A LV 960379A LV 11784 B LV11784 B LV 11784B
- Authority
- LV
- Latvia
- Prior art keywords
- fibrin
- fibrinogen
- antibody
- monoclonal antibody
- quot
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/204,015 US5487892A (en) | 1994-02-24 | 1994-02-24 | Method for treating thrombotic disease using a fibrin specific monoclonal antibody |
PCT/US1995/001825 WO1995022986A1 (en) | 1994-02-24 | 1995-02-21 | Fibrin-specific antibody for use as an antithrombotic agent |
Publications (2)
Publication Number | Publication Date |
---|---|
LV11784A LV11784A (lv) | 1997-06-20 |
LV11784B true LV11784B (en) | 1997-12-20 |
Family
ID=22756260
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LVP-96-379A LV11784B (en) | 1994-02-24 | 1996-09-23 | Fibrin-specific antibody for use as an antithrombotic agent |
Country Status (26)
Country | Link |
---|---|
US (1) | US5487892A (fi) |
EP (1) | EP0749320A4 (fi) |
JP (1) | JPH09509429A (fi) |
KR (1) | KR970701063A (fi) |
CN (1) | CN1146157A (fi) |
AU (1) | AU708897B2 (fi) |
BG (1) | BG62476B1 (fi) |
BR (1) | BR9506949A (fi) |
CA (1) | CA2183953A1 (fi) |
CZ (1) | CZ246496A3 (fi) |
FI (1) | FI963288A0 (fi) |
GE (1) | GEP20002257B (fi) |
HU (1) | HUT76536A (fi) |
LT (1) | LT4192B (fi) |
LV (1) | LV11784B (fi) |
MD (1) | MD1521G2 (fi) |
MX (1) | MX9603602A (fi) |
NO (1) | NO963497L (fi) |
NZ (1) | NZ281481A (fi) |
PL (1) | PL316005A1 (fi) |
RU (1) | RU2152801C2 (fi) |
SG (1) | SG53279A1 (fi) |
SK (1) | SK108496A3 (fi) |
TJ (1) | TJ301B (fi) |
UA (1) | UA41984C2 (fi) |
WO (1) | WO1995022986A1 (fi) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5582862A (en) * | 1988-04-04 | 1996-12-10 | General Hospital Corporation | Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin |
US5453359A (en) * | 1988-06-13 | 1995-09-26 | American Biogenetic Sciences, Inc. | Immunoassay and kit for in vitro detection of soluble DesAABB fibrin polymers |
US5817768A (en) * | 1995-06-07 | 1998-10-06 | The New York Blood Center, Inc. | Monospecific antibodies against a subunit of fibrinogen |
US6727102B1 (en) | 1997-06-20 | 2004-04-27 | Leuven Research & Development Vzw | Assays, antibodies, and standards for detection of oxidized and MDA-modified low density lipoproteins |
US6309888B1 (en) * | 1998-09-04 | 2001-10-30 | Leuven Research & Development Vzw | Detection and determination of the stages of coronary artery disease |
IL134828A0 (en) * | 2000-03-01 | 2001-05-20 | Eship 4U Com Inc | System for delivery and receipt of dispatches especially useful for e-commerce |
US20050181451A1 (en) * | 2004-02-12 | 2005-08-18 | Bates Harold M. | Detection of asymptomatic coronary artery disease using atherogenic proteins and acute phase reactants |
US7829294B2 (en) * | 2004-12-28 | 2010-11-09 | Daiichi Pure Chemicals Co., Ltd. | Anti-human soluble fibrin monoclonal antibody and immunological assay method using the antibody |
CA2831572C (en) | 2011-05-02 | 2019-11-26 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
EP3586874A1 (en) | 2012-08-14 | 2020-01-01 | IBC Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
PL2900277T3 (pl) | 2012-12-13 | 2022-05-16 | Immunomedics, Inc. | Dawkowanie immunokoniugatów przeciwciał i sn-38 dla poprawy skuteczności i zmniejszenia toksyczności |
CN110563258A (zh) * | 2019-09-06 | 2019-12-13 | 广东石油化工学院 | 一种猪场废水厌氧产氢与达标排放处理方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU572125B2 (en) * | 1983-03-17 | 1988-05-05 | Mabco Limited | Monoclonal antibodies with specificity for crosslinked fibrin and their diagnotic uses |
US4722903A (en) * | 1983-11-14 | 1988-02-02 | New York Blood Center, Inc. | Monoclonal antibodies specific to in vivo fragments derived from human fibrinogen, human fiberin I or human fibrin II |
US4916070A (en) * | 1986-04-14 | 1990-04-10 | The General Hospital Corporation | Fibrin-specific antibodies and method of screening for the antibodies |
WO1987006240A1 (en) * | 1986-04-14 | 1987-10-22 | The General Hospital Corporation | Heterobifunctional antibodies and method of use |
WO1988001514A1 (en) * | 1986-08-25 | 1988-03-10 | American Biogenetic Sciences, Inc. | Monoclonal antibodies to fibrin |
DE3701812A1 (de) * | 1987-01-22 | 1988-08-04 | Max Planck Gesellschaft | Fibrinspezifischer antikoerper, verfahren zur seiner herstellung und seine verwendung |
US5091512A (en) * | 1988-06-13 | 1992-02-25 | American Biogenetic Sciences, Inc. | Fibrinogen-specific monoclonal antibody |
US5223410A (en) * | 1988-06-13 | 1993-06-29 | American Biogenetic Sciences, Inc. | Method for production of antibodies utilizing an antigen-free animal |
EP0710720A1 (en) * | 1988-06-13 | 1996-05-08 | American Biogenetic Sciences, Inc. | Method for the production of monoclonal antibodies utilizing a germfree animal |
US5120834A (en) * | 1988-06-13 | 1992-06-09 | American Biogenetic Sciences, Inc. | Fibrin-specific monoclonal antibody |
US5206140A (en) | 1988-06-24 | 1993-04-27 | Research Corporation Technologies, Inc. | Assay for soluble crosslinked fibrin polymers |
CA2052283A1 (en) * | 1990-09-27 | 1992-03-28 | Edgar Haber | Recombinant hybrid immunoglobulin molecules and method of use |
-
1994
- 1994-02-24 US US08/204,015 patent/US5487892A/en not_active Expired - Lifetime
-
1995
- 1995-02-21 MX MX9603602A patent/MX9603602A/es unknown
- 1995-02-21 EP EP95910251A patent/EP0749320A4/en not_active Withdrawn
- 1995-02-21 CN CN95192673A patent/CN1146157A/zh active Pending
- 1995-02-21 BR BR9506949A patent/BR9506949A/pt not_active Application Discontinuation
- 1995-02-21 MD MD96-0334A patent/MD1521G2/ro unknown
- 1995-02-21 JP JP7522375A patent/JPH09509429A/ja not_active Ceased
- 1995-02-21 KR KR1019960704600A patent/KR970701063A/ko not_active Application Discontinuation
- 1995-02-21 SG SG1996009046A patent/SG53279A1/en unknown
- 1995-02-21 SK SK1084-96A patent/SK108496A3/sk unknown
- 1995-02-21 CA CA002183953A patent/CA2183953A1/en not_active Abandoned
- 1995-02-21 GE GEAP19953380A patent/GEP20002257B/en unknown
- 1995-02-21 UA UA96093639A patent/UA41984C2/uk unknown
- 1995-02-21 CZ CZ962464A patent/CZ246496A3/cs unknown
- 1995-02-21 WO PCT/US1995/001825 patent/WO1995022986A1/en not_active Application Discontinuation
- 1995-02-21 TJ TJ96000411A patent/TJ301B/xx unknown
- 1995-02-21 NZ NZ281481A patent/NZ281481A/en unknown
- 1995-02-21 AU AU18434/95A patent/AU708897B2/en not_active Ceased
- 1995-02-21 PL PL95316005A patent/PL316005A1/xx unknown
- 1995-02-21 RU RU96119386/14A patent/RU2152801C2/ru active
- 1995-02-21 HU HU9602337A patent/HUT76536A/hu unknown
-
1996
- 1996-08-22 NO NO963497A patent/NO963497L/no not_active Application Discontinuation
- 1996-08-23 FI FI963288A patent/FI963288A0/fi unknown
- 1996-09-23 BG BG100863A patent/BG62476B1/bg unknown
- 1996-09-23 LV LVP-96-379A patent/LV11784B/en unknown
- 1996-09-24 LT LT96-140A patent/LT4192B/lt not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
US5487892A (en) | 1996-01-30 |
BR9506949A (pt) | 1997-09-23 |
MD960334A (en) | 1997-09-30 |
BG100863A (en) | 1997-08-29 |
CA2183953A1 (en) | 1995-08-31 |
RU2152801C2 (ru) | 2000-07-20 |
FI963288A (fi) | 1996-08-23 |
UA41984C2 (uk) | 2001-10-15 |
SK108496A3 (en) | 1997-10-08 |
EP0749320A1 (en) | 1996-12-27 |
HUT76536A (en) | 1997-09-29 |
GEP20002257B (en) | 2000-10-25 |
JPH09509429A (ja) | 1997-09-22 |
WO1995022986A1 (en) | 1995-08-31 |
EP0749320A4 (en) | 1997-06-18 |
MD1521F2 (en) | 2000-08-31 |
AU708897B2 (en) | 1999-08-12 |
CN1146157A (zh) | 1997-03-26 |
AU1843495A (en) | 1995-09-11 |
HU9602337D0 (en) | 1996-10-28 |
LT4192B (en) | 1997-07-25 |
NO963497D0 (no) | 1996-08-22 |
SG53279A1 (en) | 1998-09-28 |
MX9603602A (es) | 1997-05-31 |
PL316005A1 (en) | 1996-12-23 |
KR970701063A (ko) | 1997-03-17 |
FI963288A0 (fi) | 1996-08-23 |
MD1521G2 (ro) | 2001-03-31 |
LT96140A (en) | 1997-03-25 |
NZ281481A (en) | 1998-07-28 |
BG62476B1 (bg) | 1999-12-30 |
LV11784A (lv) | 1997-06-20 |
CZ246496A3 (en) | 1997-04-16 |
TJ301B (en) | 2001-08-06 |
NO963497L (no) | 1996-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200129600A1 (en) | Combination therapy using a factor xii inhibitor and a c-1 inhibitor | |
US7754215B2 (en) | Antithrombotic therapy with antibodies binding to the A3 domain of von Willebrand factor (VWF) | |
JP6705785B2 (ja) | トロンビン結合性抗体分子及びその使用 | |
US5487892A (en) | Method for treating thrombotic disease using a fibrin specific monoclonal antibody | |
PT975672E (pt) | Anticorpos para inibir a coagulação sanguínea e métodos para a sua utilização | |
JPH06502307A (ja) | 血液凝固タンパク質のアンタゴニストおよびその利用方法 | |
JP6894993B2 (ja) | 血漿タンパク質にコンジュゲートしたヘパリンを含む治療用apac分子 | |
US5922322A (en) | Fibrin(ogen) degradation and clot lysis by fibrinolytic matrix metalloproteinase | |
US20090010934A1 (en) | Cell lines, ligands and antibody fragments for use in pharmaceutical compositions for preventing and treating haemostasis disorders | |
BANG | Physiology and biochemistry of fibrinolysis | |
JP2002516296A (ja) | 凝塊形成を阻害する方法 | |
JPH03504717A (ja) | 血餅溶解の促進のための組成物及び方法 | |
EP1060747A2 (en) | Fibrin(ogen) degradation and clot lysis by fibrinolytic metalloproteinase | |
WO1997002291A1 (en) | Method of producing fibrin-specific antibodies using soluble fibrin polymers as an immunogen | |
Harrington et al. | Clinical development of bivalirudin | |
Prentice | Abnormal Haemostasis as Risk Factor and Predictor of Vascular Occlusions |